Johnson & Johnson Finds Growth Beyond Legacy Drugs, Lifts 2026 Outlook
Johnson & Johnson (NYSE: JNJ ) on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full-year sales and adjusted earnings guidance as strength in its Innovative Medicine and MedTech businesses offset continued pressure from several legacy products. Adjusted earnings rose 4.